IBDEI15Y ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20809,0)
 ;;=287.1^^118^1254^22
 ;;^UTILITY(U,$J,358.3,20809,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20809,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,20809,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,20809,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,20810,0)
 ;;=287.2^^118^1254^17
 ;;^UTILITY(U,$J,358.3,20810,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20810,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,20810,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,20810,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,20811,0)
 ;;=287.31^^118^1254^13
 ;;^UTILITY(U,$J,358.3,20811,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20811,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,20811,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,20811,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,20812,0)
 ;;=287.32^^118^1254^11
 ;;^UTILITY(U,$J,358.3,20812,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20812,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,20812,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,20812,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,20813,0)
 ;;=287.41^^118^1254^20
 ;;^UTILITY(U,$J,358.3,20813,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20813,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,20813,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,20813,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,20814,0)
 ;;=287.49^^118^1254^18
 ;;^UTILITY(U,$J,358.3,20814,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20814,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,20814,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,20814,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,20815,0)
 ;;=287.8^^118^1254^19
 ;;^UTILITY(U,$J,358.3,20815,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20815,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,20815,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,20815,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,20816,0)
 ;;=287.9^^118^1254^27
 ;;^UTILITY(U,$J,358.3,20816,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20816,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,20816,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,20816,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,20817,0)
 ;;=238.72^^118^1254^14
 ;;^UTILITY(U,$J,358.3,20817,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20817,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,20817,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,20817,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,20818,0)
 ;;=238.73^^118^1254^12
 ;;^UTILITY(U,$J,358.3,20818,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20818,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,20818,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,20818,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,20819,0)
 ;;=238.75^^118^1254^15
 ;;^UTILITY(U,$J,358.3,20819,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20819,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,20819,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,20819,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,20820,0)
 ;;=205.00^^118^1255^32
 ;;^UTILITY(U,$J,358.3,20820,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20820,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,20820,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20820,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,20821,0)
 ;;=205.01^^118^1255^31
 ;;^UTILITY(U,$J,358.3,20821,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20821,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,20821,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20821,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,20822,0)
 ;;=205.10^^118^1255^18
